Fig. 1From: Targeting HER2-positive breast cancer cells by a combination of dasatinib and BMS-202: Insight into the molecular pathwaysBoth HER2-positive breast cancer cell lines, SKBR3 and ZR75, express drug targets: Src and PD-L1. (a) The expression of Src in SKBR3 and ZR75 cells is shown by Western blot. Data are expressed as src expression ± SEM. (b) PD-L1 expression in SKBR3 and (c) ZR75 cells shown by FACS analysisBack to article page